Filtros de búsqueda

Lista de obras de Rafael Rosell

10(th) Congress on Lung Cancer-updates on clinical trials: goal

artículo científico

14-3-3sigma methylation in pretreatment serum circulating DNA of cisplatin-plus-gemcitabine-treated advanced non-small-cell lung cancer patients predicts survival: The Spanish Lung Cancer Group

artículo científico publicado en 2005

A Prognostic DNA Methylation Signature for Stage I Non–Small-Cell Lung Cancer

article

A critical question for cancer therapy: what new targets exist?

artículo científico publicado en 2014

A gene signature combining the tissue expression of three angiogenic factors is a prognostic marker in early-stage non-small cell lung cancer.

artículo científico publicado en 2013

A multicenter randomized phase IIb efficacy study of Vx-001, a peptide-based cancer vaccine as maintenance treatment in advanced non-small-cell lung cancer: treatment rationale and protocol dynamics

artículo científico publicado en 2013

A multigene assay is prognostic of survival in patients with early-stage lung adenocarcinoma

artículo científico publicado en 2008

A sensitive method for detecting EGFR mutations in non-small cell lung cancer samples with few tumor cells

artículo científico publicado en 2008

ALK and ROS1 non-small-cell lung cancer: two molecular subgroups sensitive to targeted therapy

artículo científico publicado en 2014

ALK translocation and crizotinib in non-small cell lung cancer: an evolving paradigm in oncology drug development

artículo científico publicado en 2012

AXL mediates resistance to PI3Kα inhibition by activating the EGFR/PKC/mTOR axis in head and neck and esophageal squamous cell carcinomas

artículo científico publicado en 2015

AXL-associated tumor inflammation as a poor prognostic signature in chemotherapy-treated triple-negative breast cancer patients

artículo científico publicado en 2016

Abstract 265: Cotargeting EGFR, STAT3 and Src-Notch pathways: a promising approach to improve the efficacy of EGFR-TKIs in the treatment of NSCLC patients

Acquired Resistance to Erlotinib in EGFR Mutation-Positive Lung Adenocarcinoma among Hispanics (CLICaP).

artículo científico publicado en 2017

Activation of signal transducer and activator of transcription 3 (STAT3) signaling in EGFR mutant non-small-cell lung cancer (NSCLC)

artículo científico publicado en 2017

Activation of the AXL kinase causes resistance to EGFR-targeted therapy in lung cancer

artículo científico publicado en 2012

Activation of viral defense signaling in cancer

Activity and safety of brigatinib in ALK-rearranged non-small-cell lung cancer and other malignancies: a single-arm, open-label, phase 1/2 trial

artículo científico publicado en 2016

Adjuvant chemotherapy for resected early-stage non-small cell lung cancer

artículo científico publicado en 2015

Adjuvant cisplatin and vinorelbine for completely resected non-small cell lung cancer: subgroup analysis of the Lung Adjuvant Cisplatin Evaluation

artículo científico publicado en 2010

Adjuvant therapy for resected EGFR-mutant non-small-cell lung cancer.

artículo científico publicado en 2018

Adjuvant vinorelbine plus cisplatin versus observation in patients with completely resected stage IB-IIIA non-small-cell lung cancer (Adjuvant Navelbine International Trialist Association [ANITA]): a randomised controlled trial

artículo científico publicado en 2006

Advances and challenges in the molecular biology and treatment of glioblastoma-is there any hope for the future?

artículo científico publicado en 2015

Advances in immunotherapy for treatment of lung cancer

artículo científico publicado en 2015

Alectinib: a selective, next-generation ALK inhibitor for treatment of ALK-rearranged non-small-cell lung cancer

artículo científico publicado en 2015

An innovative mesothelioma treatment based on miR-16 mimic loaded EGFR targeted minicells (TargomiRs).

artículo científico publicado en 2018

An update on liquid biopsy analysis for diagnostic and monitoring applications in non-small cell lung cancer

artículo científico publicado en 2017

Analysis of the prognostic value of soluble epidermal growth factor receptor plasma concentration in advanced non-small-cell lung cancer patients.

artículo científico publicado en 2011

Anaplastic lymphoma kinase inhibitors in phase I and phase II clinical trials for non-small cell lung cancer

artículo científico publicado en 2017

Annual or biennial lung cancer CT screening?

artículo científico publicado en 2016

Anti-Epidermal Growth Factor Vaccine Antibodies Enhance the Efficacy of Tyrosine Kinase Inhibitors and Delay the Emergence of Resistance in EGFR Mutant Lung Cancer Cells.

artículo científico publicado en 2018

Applications of genomics in NSCLC.

artículo científico publicado en 2005

Are we ready to use biomarkers for staging, prognosis and treatment selection in early-stage non-small-cell lung cancer?

artículo científico publicado en 2013

Assays for predicting and monitoring responses to lung cancer immunotherapy

artículo científico

Association of EGFR L858R Mutation in Circulating Free DNA With Survival in the EURTAC Trial

artículo científico

BIM and mTOR expression levels predict outcome to erlotinib in EGFR-mutant non-small-cell lung cancer

artículo científico publicado en 2015

BIM deletion polymorphisms in Hispanic patients with non-small cell lung cancer carriers of EGFR mutations

artículo científico publicado en 2016

BRAF mutant non-small cell lung cancer and treatment with BRAF inhibitors

artículo científico publicado en 2013

BRAF mutation analysis in circulating free tumor DNA of melanoma patients treated with BRAF inhibitors

artículo científico

BRAFV600E and BRAF-inactivating mutations in NSCLC.

artículo científico publicado en 2017

BRCA1 mRNA expression levels as an indicator of chemoresistance in lung cancer

artículo científico publicado en 2004

BRCA1, LMO4, and CtIP mRNA expression in erlotinib-treated non-small-cell lung cancer patients with EGFR mutations

artículo científico publicado en 2013

BRCA1: a new genomic marker for non-small-cell lung cancer

artículo científico publicado en 2008

BRCA1: a novel prognostic factor in resected non-small-cell lung cancer

artículo científico publicado en 2007

Beta-tubulin mutational analysis: tantalizing findings

artículo científico publicado en 2002

Beyond platinum treatment for NSCLC: what does the future hold?

artículo científico publicado en 2017

Biomarkers in lung oncology

scientific article published on 13 May 2010

Blood-based CHRNA3 single nucleotide polymorphism and outcome in advanced non-small-cell lung cancer patients

artículo científico publicado en 2009

Brain metastases in patients with EGFR-mutant non-small-cell lung cancer

artículo científico publicado en 2017

Bronchioloalveolar carcinoma: a review

artículo científico publicado en 2006

CK-coated magnetic-based beads as a tool to isolate circulating tumor cells (CTCs) in human tumors

artículo científico publicado en 2013

Can we customize chemotherapy? Individualizing cytotoxic regimens in advanced non-small-cell lung cancer

artículo científico

Cancer stem cells and immunoresistance: clinical implications and solutions

artículo científico publicado en 2015

Cancer stem cells in small cell lung cancer

artículo científico publicado en 2016

Cancer treatments: can we find treasures at the bottom of the sea?

artículo científico publicado en 2009

Challenges and unanswered questions for the next decade of immune-oncology research in NSCLC

article by Niki Karachaliou et al published December 2018 in Translational lung cancer research

Chemotherapy-induced neutropenia does not correlate with DNA repair gene polymorphisms and treatment efficacy in advanced non-small-cell lung cancer patients

artículo científico publicado en 2011

Circulating DNA is a useful prognostic factor in patients with advanced non-small cell lung cancer.

artículo científico publicado en 2011

Cisplatin plus vinorelbine as first-line treatment for advanced non-small-cell lung cancer: Is a hemogram on day 8 essential?

artículo científico publicado en 2009

Cisplatin plus weekly CPT-11/docetaxel in advanced esophagogastric cancer: a phase I study with pharmacogenetic assessment of XPD, XRCC3 and UGT1A1 polymorphisms

artículo científico publicado en 2008

Cisplatin- versus carboplatin-based chemotherapy in first-line treatment of advanced non-small-cell lung cancer: an individual patient data meta-analysis

artículo científico publicado en 2007

Clinical assessment of immune-related adverse events.

artículo científico publicado en 2018

Clinical experience with erlotinib in non-small-cell lung cancer

artículo científico publicado en 2006

Clinical outcomes in non-small-cell lung cancer patients with EGFR mutations: pooled analysis

artículo científico publicado en 2010

Clinical significance of hypoxia-inducible factor-1a messenger RNA expression in locally advanced non-small-cell lung cancer after platinum agent and gemcitabine chemotherapy followed by surgery

artículo científico publicado en 2005

Cloning and characterization of the promoter of human Wnt inhibitory factor-1.

artículo científico publicado en 2004

Co-mutations in EGFR driven non-small cell lung cancer

Combination of immunotherapy with chemotherapy and radiotherapy in lung cancer: is this the beginning of the end for cancer?

artículo científico publicado en 2018

Combination of immunotherapy with targeted therapies in advanced non-small cell lung cancer (NSCLC).

artículo científico publicado en 2018

Comprehensive molecular screening: from the RT-PCR to the RNA-seq

artículo científico publicado en 2013

Consensus for EGFR mutation testing in non-small cell lung cancer: results from a European workshop

scientific article published on October 2010

Convergent Akt activation drives acquired EGFR inhibitor resistance in lung cancer

artículo científico publicado en 2017

Coordinated strategies for early detection of lung cancer.

artículo científico publicado en 2018

Correlation of DNA Repair Gene Polymorphisms With Clinical Outcome in Patients With Locally Advanced Non-Small-Cell Lung Cancer Receiving Induction Chemotherapy Followed by Surgery

artículo científico publicado en 2016

Crossing the rubicon in lung adenocarcinoma: the conundrum of EGFR tyrosine kinase mutations

artículo científico publicado en 2005

Current concepts in bronchioloalveolar carcinoma biology

artículo científico publicado en 2006

Customized chemotherapy in metastatic non-small cell lung cancer (NSCLC)

artículo científico

Customized treatment in non-small-cell lung cancer based on EGFR mutations and BRCA1 mRNA expression

artículo científico publicado en 2009

DNA repair and cisplatin resistance in non-small-cell lung cancer

artículo científico publicado en 2002

Detection of EGFR mutations with mutation-specific antibodies in stage IV non-small-cell lung cancer

artículo científico publicado en 2010

Determinants of response and resistance to cytotoxics

artículo científico publicado en 2002

Disulfide isomerase family-6 mediates cisplatin resistance by interfering with apoptosis and autophagy

Early evolution of BRAFV600 status in the blood of melanoma patients correlates with clinical outcome and identifies patients refractory to therapy.

artículo científico publicado en 2018

Early2 factor (E2F) deregulation is a prognostic and predictive biomarker in lung adenocarcinoma

artículo científico publicado en 2016

Economic Analysis of First-Line Treatment with Erlotinib in an EGFR-Mutated Population with Advanced NSCLC.

artículo científico publicado en 2016

Effect of the methylenetetrahydrofolate reductase C677T polymorphism on patients with cisplatin/gemcitabine-treated stage IV non-small-cell lung cancer

artículo científico publicado en 2004

Emerging drugs for non-small-cell lung cancer

artículo científico publicado en 2007

Endobronchial ultrasound-guided transbronchial needle aspiration in the diagnosis of intrathoracic lymph node metastases from extrathoracic malignancies

artículo científico publicado en 2012

Epidermal growth factor receptor activation: how exon 19 and 21 mutations changed our understanding of the pathway

artículo científico publicado en 2006

Epidermal growth factor receptor tyrosine kinase inhibitors as first-line treatment in advanced nonsmall-cell lung cancer

scientific article published on March 2010

Epigenetic alterations of tumor marker microRNAs: Towards new cancer therapies

artículo científico publicado el 1 de diciembre de 2010

Erlotinib and bevacizumab in patients with advanced non-small-cell lung cancer and activating EGFR mutations (BELIEF): an international, multicentre, single-arm, phase 2 trial

artículo científico publicado en 2017

Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial

artículo científico publicado en 2012

Erlotinib-associated rash in patients with EGFR mutation-positive non-small-cell lung cancer treated in the EURTAC trial

artículo científico publicado en 2015

Erratum to Assays for predicting and monitoring responses to lung cancer immunotherapy

artículo científico publicado en 2015

Evaluation of Biomarkers for HER3-targeted Therapies in Cancer

artículo científico publicado en 2015

Expression Profiles and Clinicopathologic Features in Early Resected Non-small-cell Lung Cancer

artículo científico publicado en 2014

FAS and NF-κB signalling modulate dependence of lung cancers on mutant EGFR.

artículo científico publicado en 2011

First-line therapy and methylation status of CHFR in serum influence outcome to chemotherapy versus EGFR tyrosine kinase inhibitors as second-line therapy in stage IV non-small-cell lung cancer patients

artículo científico publicado en 2010

From the bench to the bed: individualizing treatment in non-small-cell lung cancer

artículo científico publicado en 2006

Front-line erlotinib in unselected patients with advanced NSCLC and poor performance status - the TOPICAL study

artículo científico publicado en 2013

Future directions in the second-line treatment of non-small cell lung cancer

artículo científico publicado en 2006

Gefitinib in combination with gemcitabine and cisplatin in advanced non-small-cell lung cancer: a phase III trial--INTACT 1.

artículo científico publicado en 2004

Gefitinib in combination with paclitaxel and carboplatin in advanced non-small-cell lung cancer: a phase III trial--INTACT 2.

artículo científico publicado en 2004

Gefitinib or Erlotinib vs Chemotherapy for EGFR Mutation-Positive Lung Cancer: Individual Patient Data Meta-Analysis of Overall Survival

artículo científico publicado en 2017

Gene expression as a predictive marker of outcome in stage IIB-IIIA-IIIB non-small cell lung cancer after induction gemcitabine-based chemotherapy followed by resectional surgery

artículo científico publicado en 2004

Genetic testing for chemotherapy in non-small cell lung cancer

artículo científico publicado en 2003

Genetics and biomarkers in personalisation of lung cancer treatment

artículo científico publicado en 2013

Genome-Wide Association Study of Survival in Non–Small Cell Lung Cancer Patients Receiving Platinum-Based Chemotherapy ⬇️

artículo científico publicado el 11 de abril de 2011

Genotyping non-small cell lung cancer (NSCLC) in Latin America

artículo científico publicado en 2011

HER3 as a Therapeutic Target in Cancer

artículo científico publicado en 2016

High BIM mRNA levels are associated with longer survival in advanced gastric cancer

artículo científico publicado en 2017

Homage to the titans of Chinese investigation and the race for lung cancer curability

artículo científico publicado en 2017

How to optimize the treatment strategy for patients with EGFR-mutant stage IA lung adenocarcinoma: an international multidisciplinary team.

artículo científico publicado en 2018

Human endogenous retroviruses and cancer

artículo científico publicado en 2016

IL-6/gp130/STAT3 signaling axis in cancer and the presence of in-frame gp130 somatic deletions in inflammatory hepatocellular tumors

artículo científico publicado en 2009

Identification of ALK, ROS1, and RET Fusions by a Multiplexed mRNA-Based Assay in Formalin-Fixed, Paraffin-Embedded Samples from Advanced Non-Small-Cell Lung Cancer Patients

artículo científico publicado en 2017

Immunotherapy meets targeted therapy: will this team end the war against cancer?

artículo científico publicado en 2015

Impact of Specific Epidermal Growth Factor Receptor (EGFR) Mutations and Clinical Characteristics on Outcomes After Treatment With EGFR Tyrosine Kinase Inhibitors Versus Chemotherapy in EGFR-Mutant Lung Cancer: A Meta-Analysis.

artículo científico publicado en 2015

Impact of postoperative radiation therapy on survival in patients with complete resection and stage I, II, or IIIA non-small-cell lung cancer treated with adjuvant chemotherapy: the adjuvant Navelbine International Trialist Association (ANITA) Rando

artículo científico publicado en 2008

Improvement in Overall Survival in a Randomized Study That Compared Dacomitinib With Gefitinib in Patients With Advanced Non-Small-Cell Lung Cancer and EGFR-Activating Mutations.

artículo científico publicado en 2018

Inhibition of MEK, a canonical KRAS pathway effector in mutant NSCLC

International association for the study of lung cancer/american thoracic society/european respiratory society international multidisciplinary classification of lung adenocarcinoma

artículo científico publicado en 2011

Interstitial lung disease arising from erlotinib treatment in a Caucasian patient.

artículo científico publicado en 2014

Is there a prognostic role of K-ras point mutations in the serum of patients with advanced non-small cell lung cancer?

artículo científico publicado en 2005

KRAS mutations in lung cancer

artículo científico publicado en 2012

Liquid Biopsy in Non-Small Cell Lung Cancer

artículo científico publicado en 2016

Liquid biopsy for lung cancer early detection.

artículo científico publicado en 2018

Long-term survival associated with complete resection after induction chemotherapy in stage IIIA (N2) and IIIB (T4N0-1) non small-cell lung cancer patients: the Spanish Lung Cancer Group Trial 9901.

artículo científico publicado en 2007

Loss of activating EGFR mutant gene contributes to acquired resistance to EGFR tyrosine kinase inhibitors in lung cancer cells

artículo científico publicado en 2012

Low ERCC1 expression correlates with prolonged survival after cisplatin plus gemcitabine chemotherapy in non-small cell lung cancer.

artículo científico publicado en 2002

Low RAP80 mRNA expression correlates with shorter survival in sporadic high-grade serous ovarian carcinoma

artículo científico publicado en 2016

Lung adjuvant cisplatin evaluation: a pooled analysis by the LACE Collaborative Group

artículo científico publicado en 2008

Lung cancer and treatment in elderly patients: the Achilles Study.

artículo científico publicado en 2009

Lung cancer in 2014: optimizing lung cancer treatment approaches

artículo científico

Lung cancer: Using ctDNA to track EGFR and KRAS mutations in advanced-stage disease

artículo científico publicado en 2016

Lungscape: resected non-small-cell lung cancer outcome by clinical and pathological parameters

MET overexpression and amplification define a distinct molecular subgroup for targeted therapies in gastric cancer

artículo científico publicado en 2015

Main histologic types of non-small-cell lung cancer differ in expression of prognosis-related genes

artículo científico publicado en 2013

Mediating resistance in oncogene-driven cancers

artículo científico publicado en 2013

Meta-analysis of individual patient data from randomized trials of chemotherapy plus cetuximab as first-line treatment for advanced non-small cell lung cancer

artículo científico publicado en 2013

Methylation patterns and K-ras mutations in tumor and paired serum of resected non-small-cell lung cancer patients ⬇️

artículo científico publicado el 25 de abril de 2003

Molecular Bases for Combinatorial Treatment Strategies in Patients with KRAS Mutant Lung Adenocarcinoma and Squamous Cell Lung Carcinoma

Molecular biomarkers for predicting chemotherapy response in lung cancer

artículo científico

Molecular markers and targeted therapy with novel agents: prospects in the treatment of non-small cell lung cancer

artículo científico publicado en 2002

Molecular predictors of response to chemotherapy in lung cancer

artículo científico publicado en 2004

Mouse p53-deficient cancer models as platforms for obtaining genomic predictors of human cancer clinical outcomes

artículo científico publicado en 2012

Moving towards molecular-guided treatments: erlotinib and clinical outcomes in non-small-cell lung cancer patients

artículo científico publicado en 2013

Multicenter, phase II trial of sunitinib in previously treated, advanced non-small-cell lung cancer

artículo científico publicado en 2008

Multigene Mutation Profiling and Clinical Characteristics of Small-Cell Lung Cancer in Never-Smokers vs. Heavy Smokers (Geno1.3-CLICaP)

article published in 2019

Mutations in the tyrosine kinase domain of the EGFR gene associated with gefitinib response in non-small-cell lung cancer

artículo científico publicado en 2005

Neoadjuvant treatment of early-stage resectable non-small-cell lung cancer

artículo científico publicado en 2004

Neutrophils dominate the immune landscape of non-small cell lung cancer

artículo científico publicado en 2017

No evidence of an association of ERCC1 and ERCC2 polymorphisms with clinical outcomes of platinum-based chemotherapies in non-small cell lung cancer: a meta-analysis

artículo científico publicado en 2010

Non-small-cell lung cancer harbouring mutations in the EGFR kinase domain

artículo científico publicado en 2010

Non-small-cell lung cancer.

artículo científico publicado en 2015

Nondisruptive p53 mutations are associated with shorter survival in patients with advanced non-small cell lung cancer.

artículo científico publicado en 2014

Nucleotide excision repair pathways involved in Cisplatin resistance in non-small-cell lung cancer

artículo científico publicado en 2003

O.01: Acquired Resistance to EGFR-TKIs in EGFR-Mutant Lung Adenocarcinoma Among Hispanics (RBIOP-CLICaP).

artículo científico publicado en 2016

O6-methyl-guanine-DNA methyltransferase methylation in serum and tumor DNA predicts response to 1,3-bis(2-chloroethyl)-1-nitrosourea but not to temozolamide plus cisplatin in glioblastoma multiforme

artículo científico publicado en 2003

Optimal detection of ALK rearranged lung adenocarcinomas

artículo científico publicado en 2013

Optimization of genetics to create therapies for metastatic (stage IV) non-small-cell lung cancer

scientific article published on July 2010

Osimertinib in the treatment of non-small-cell lung cancer: design, development and place in therapy

artículo científico

Osimertinib in untreated epidermal growth factor receptor (EGFR)-mutated advanced non-small cell lung cancer.

artículo científico publicado en 2018

Other targeted drugs in melanoma

artículo científico publicado en 2015

Overexpression of choline kinase is a frequent feature in human tumor-derived cell lines and in lung, prostate, and colorectal human cancers

artículo científico publicado en 2002

P1.42 (also presented as PD2.04): PEM/CBP/BEV Followed by Maintenance PEM/BEV in Hispanic Patients With NSCLC: Outcomes According to TS, ERCC1 and VEGF: Track: Advanced NSCLC.

artículo científico publicado en 2016

P2.04: Characteristics and Long Term Outcomes of Advanced Pleural Mesothelioma in Latin America (MeSO-CLICaP): Track: SCLC, Mesothelioma, Thymoma.

artículo científico publicado en 2016

PD-L1 expression associated with better response to EGFR tyrosine kinase inhibitors

artículo científico publicado en 2015

PET/CT fusion scan in lung cancer: current recommendations and innovations

artículo científico publicado en 2006

PIK3CA mutations and BRCA1 expression in breast cancer: potential biomarkers for chemoresistance

artículo científico publicado en 2008

Pathway Targeted Immunotherapy: Rationale and Evidence of Durable Clinical Responses with a Novel, EGF-directed Agent for Advanced NSCLC.

artículo científico publicado en 2016

Pemetrexed combination therapy in the treatment of non-small cell lung cancer

artículo científico publicado en 2002

Pemetrexed combined with oxaliplatin or carboplatin as first-line treatment in advanced non-small cell lung cancer: a multicenter, randomized, phase II trial

artículo científico publicado en 2005

Pemetrexed in front-line chemotherapy for advanced non-small-cell lung cancer

artículo científico publicado en 2004

Pemetrexed/Carboplatin/Bevacizumab followed by Maintenance Pemetrexed/Bevacizumab in Hispanic Patients with Non-Squamous Non-Small Cell Lung Cancer: Outcomes according to Thymidylate Synthase Expression

artículo científico publicado en 2016

Personalized treatment in advanced ALK-positive non-small cell lung cancer: from bench to clinical practice

artículo científico publicado en 2016

Personalized treatment of early-stage non-small-cell lung cancer: the challenging role of EGFR inhibitors

artículo científico

Pharmacogenetics of EGFR in lung cancer: perspectives and clinical applications

artículo científico

Pharmacogenomic approaches to individualizing chemotherapy for non-small-cell lung cancer: current status and new directions

artículo científico publicado en 2008

Pharmacogenomic strategies for developing customized chemotherapy in non-small cell lung cancer

artículo científico publicado en 2002

Pharmacogenomics in lung cancer: an analysis of DNA repair gene expression in patients treated with platinum-based chemotherapy

artículo científico publicado en 2005

Pharmacogenomics in non-small-cell lung cancer chemotherapy

artículo científico publicado en 2009

Pharmacogenomics in the treatment of lung cancer: an update

artículo científico

Pharmacological management of relapsed/refractory NSCLC with chemical drugs

artículo científico publicado en 2017

Phase I, dose-escalating study of elisidepsin (Irvalec(®)), a plasma membrane-disrupting marine antitumor agent, in combination with erlotinib in patients with advanced malignant solid tumors.

artículo científico publicado en 2015

Phase I/II and pharmacokinetic study of intravenous vinflunine in combination with cisplatin for the treatment of chemonaive patients with advanced non-small-cell lung cancer

artículo científico publicado en 2010

Phase II non-randomized study of three different sequences of docetaxel and vinorelbine in patients with advanced non-small cell lung cancer

artículo científico publicado en 2002

Plasma mRNA expression levels of BRCA1 and TS as potential predictive biomarkers for chemotherapy in gastric cancer

artículo científico publicado en 2014

Platinum drugs and DNA repair mechanisms in lung cancer

artículo científico

Platinum resistance related to a functional NER pathway

artículo científico publicado en 2007

Pooled analysis of the prognostic and predictive effects of KRAS mutation status and KRAS mutation subtype in early-stage resected non-small-cell lung cancer in four trials of adjuvant chemotherapy

artículo científico publicado en 2013

Possible application of circulating free tumor DNA in non-small cell lung cancer patients

artículo científico publicado en 2017

Predicting Response to Chemotherapy With Early-Stage Lung Cancer ⬇️

artículo científico publicado el 1 de enero de 2011

Predicting resistance by selection of signaling pathways

artículo científico

Predicting the outcome of chemotherapy for lung cancer

artículo científico publicado en 2006

Predictive biomarkers in the management of EGFR mutant lung cancer ⬇️

artículo científico publicado el 1 de octubre de 2010

Predictive factors for immunotherapy in melanoma

artículo científico publicado en 2015

Predictors of long-term survival in patients with lung cancer included in the randomized Spanish Lung Cancer Group 0008 phase II trial using concomitant chemoradiation with docetaxel and carboplatin plus induction or consolidation chemotherapy

artículo científico publicado en 2009

Pretreatment EGFR T790M Mutation and BRCA1 mRNA Expression in Erlotinib-Treated Advanced Non–Small-Cell Lung Cancer Patients with EGFR Mutations ⬇️

artículo científico publicado el 13 de enero de 2011

Prognostic Effect of Tumor Lymphocytic Infiltration in Resectable Non-Small-Cell Lung Cancer

artículo científico publicado en 2016

Programmed cell death protein-1/programmed cell death ligand-1 pathway inhibition and predictive biomarkers: understanding transforming growth factor-beta role

artículo científico publicado en 2015

Prospective randomized phase III trial of etoposide/cisplatin versus high-dose epirubicin/cisplatin in small-cell lung cancer

artículo científico publicado en 2004

Quantification of unmethylated Alu (QUAlu): a tool to assess global hypomethylation in routine clinical samples

artículo científico publicado en 2016

RET inhibitors for patients with RET fusion-positive and RET wild-type non-small-cell lung cancer.

artículo científico publicado en 2016

ROR1 as a novel therapeutic target for EGFR-mutant non-small-cell lung cancer patients with the EGFR T790M mutation

artículo científico publicado en 2014

ROS1 rearrangements in lung adenocarcinoma: prognostic impact, therapeutic options and genetic variability

artículo científico publicado en 2015

Randomized phase II trial of non-platinum induction or consolidation chemotherapy plus concomitant chemoradiation in stage III NSCLC patients: mature results of the Spanish Lung Cancer Group 0008 study

artículo científico publicado en 2013

Randomized phase III trial of paclitaxel/carboplatin with or without PF-3512676 (Toll-like receptor 9 agonist) as first-line treatment for advanced non-small-cell lung cancer

artículo científico publicado en 2011

Real-time liquid biopsies become a reality in cancer treatment

artículo científico publicado en 2015

Rearranged EML4-ALK fusion transcripts sequester in circulating blood platelets and enable blood-based crizotinib response monitoring in non-small-cell lung cancer

artículo científico publicado en 2015

Recent developments in the use of immunotherapy in non-small cell lung cancer

artículo científico publicado en 2016

Recent issues in first-line treatment of advanced non-small-cell lung cancer: Results of an International Expert Panel Meeting of the Italian Association of Thoracic Oncology

artículo científico publicado en 2009

Relationship between gene mutation and lung cancer metastasis

artículo científico

Relevance of molecular characterization of circulating tumor cells in breast cancer in the era of targeted therapies

artículo científico publicado en 2013

Response to crizotinib in a non-small-cell lung cancer patient harboring an EML4-ALK fusion with an atypical LTBP1 insertion.

artículo científico publicado en 2018

Results of clinical trials with anti-programmed death 1/programmed death ligand 1 inhibitors in lung cancer

artículo científico publicado en 2015

Retrospective analysis of the prognostic role of p16 protein inactivation in plasma in patients with locally advanced non-small cell lung cancer.

artículo científico publicado en 2008

Retrospective study of efficacy and toxicity on patients older than 70 years within a randomized clinical trial of two cisplatin-based combinations in patients with small-cell lung cancer

artículo científico publicado en 2008

Rhomboids and regulation of receptor tyrosine kinase ligands shedding

artículo científico publicado en 2018

Ribonucleotide reductase M1 gene promoter activity, polymorphisms, population frequencies, and clinical relevance

artículo científico publicado en 2005

Ribonucleotide reductase messenger RNA expression and survival in gemcitabine/cisplatin-treated advanced non-small cell lung cancer patients

artículo científico publicado en 2004

Role of erlotinib in first-line and maintenance treatment of advanced non-small-cell lung cancer ⬇️

artículo científico publicado el 1 de junio de 2010

Role of genotyping in non-small cell lung cancer treatment: current status

artículo científico

SMARCA4/BRG1 Is a Novel Prognostic Biomarker Predictive of Cisplatin-Based Chemotherapy Outcomes in Resected Non-Small Cell Lung Cancer

artículo científico publicado en 2016

STAT3 as a potential immunotherapy biomarker in oncogene-addicted non-small cell lung cancer.

artículo científico publicado en 2018

Science and biology drives the immune system to cure lung cancer patients: a revolution but not without challenges.

artículo científico publicado en 2018

Screening for EGFR mutations in lung cancer.

artículo científico publicado en 2009

Second-line therapy of squamous non-small cell lung cancer: an evolving landscape

artículo científico publicado en 2017

Second-line treatment in EGFR-unselected patients: is it time to close one arm of this river's DELTA?

artículo científico publicado en 2015

Second-line treatment of advanced non-small cell lung cancer

artículo científico publicado en 2008

Setting the benchmark for tailoring treatment with EGFR tyrosine kinase inhibitors

artículo científico publicado en 2007

Signaling pathways modulating dependence of lung cancer on mutant epidermal growth factor receptor and mechanisms of intrinsic and acquired resistance to tyrosine kinase inhibitors

artículo científico publicado en 2014

Single nucleotide polymorphisms (SNPs) in non-small cell lung cancer (NSCLC) patients

artículo científico publicado en 2012

Small-cell lung cancer: where are we now and what can we expect for the future?

artículo científico publicado en 2013

Smoking habits in elderly lung cancer patients: still no changes in epidemiology? A single-center experience ⬇️

artículo científico publicado el 1 de octubre de 2010

Spotlight on ceritinib in the treatment of ALK+ NSCLC: design, development and place in therapy

artículo científico publicado en 2017

Strategies for first-line immunotherapy in squamous cell lung cancer: are combinations a game changer?

Strategies to overcome resistance to tyrosine kinase inhibitors in non-small-cell lung cancer

artículo científico

Subtype Classification of Lung Adenocarcinoma Predicts Benefit From Adjuvant Chemotherapy in Patients Undergoing Complete Resection

artículo científico publicado en 2015

Successful empirical erlotinib treatment of a mechanically ventilated patient newly diagnosed with metastatic lung adenocarcinoma

artículo científico publicado en 2014

Survival Outcomes According to TIMP1 and EGFR Expression in Heavily Treated Patients with Advanced Non-small Cell Lung Cancer who Received Biweekly Irinotecan Plus Bevacizumab

artículo científico publicado en 2017

Systemic treatment in EGFR-ALK NSCLC patients: second line therapy and beyond

artículo científico publicado en 2014

Systemic treatment in EGFR-ALK NSCLC patients: second line therapy and beyond

artículo científico

Targeted drugs in small-cell lung cancer

artículo científico publicado en 2016

Targeted treatment of mutated EGFR-expressing non-small-cell lung cancer: focus on erlotinib with companion diagnostics

artículo científico publicado en 2014

Targeting PD-1/PD-L1 in lung cancer: current perspectives

artículo científico publicado en 2015

Targeting RET in Patients With RET-Rearranged Lung Cancers: Results From the Global, Multicenter RET Registry

artículo científico publicado en 2017

Testing for excision repair cross-complementing 1 in patients with non-small-cell lung cancer for chemotherapy response

artículo científico publicado en 2007

The Hippo effector YAP promotes resistance to RAF- and MEK-targeted cancer therapies

artículo científico publicado en 2015

The Present and Future of Liquid Biopsies in Non-Small Cell Lung Cancer: Combining Four Biosources for Diagnosis, Prognosis, Prediction, and Disease Monitoring

artículo científico publicado en 2018

The Value of Early Depth of Response in Predicting Long-Term Outcome in EGFR-Mutant Lung Cancer.

artículo científico publicado en 2018

The combination of checkpoint immunotherapy and targeted therapy in cancer

artículo científico publicado en 2017

The cystic fibrosis transmembrane conductance regulator as a biomarker in non-small cell lung cancer

artículo científico publicado en 2015

The epidermal growth factor receptor (EGRF) in lung cancer

artículo científico publicado en 2015

The impact of EGFR T790M mutations and BIM mRNA expression on outcome in patients with EGFR-mutant NSCLC treated with erlotinib or chemotherapy in the randomized phase III EURTAC trial

artículo científico publicado en 2014

The impact of common and rare EGFR mutations in response to EGFR tyrosine kinase inhibitors and platinum-based chemotherapy in patients with non-small cell lung cancer.

artículo científico publicado en 2014

The impact of rare EGFR mutations on the treatment response of patients with non-small cell lung cancer.

artículo científico publicado en 2015

The predictive value of 53BP1 and BRCA1 mRNA expression in advanced non-small-cell lung cancer patients treated with first-line platinum-based chemotherapy

artículo científico publicado en 2013

The prognostic value of BRCA1 mRNA expression levels following neoadjuvant chemotherapy in breast cancer

artículo científico publicado en 2010

The promise of pharmacogenomics: gemcitabine and pemetrexed.

artículo científico publicado en 2004

The role of Wnt signaling in cancer and stem cells

artículo científico publicado en 2005

The role of smoking status on the progression-free survival of non-small cell lung cancer patients harboring activating epidermal growth factor receptor (EGFR) mutations receiving first-line EGFR tyrosine kinase inhibitor versus platinum doublet che

artículo científico publicado en 2015

The role of the clinical research coordinator--data manager--in oncology clinical trials

artículo científico publicado en 2004

Toward customized trastuzumab in HER-2/neu-overexpressing non-small-cell lung cancers

artículo científico publicado en 2004

Transcriptomic-metabolomic reprogramming in EGFR-mutant NSCLC early adaptive drug escape linking TGFβ2-bioenergetics-mitochondrial priming

artículo científico publicado en 2016

Transcripts in pretreatment biopsies from a three-arm randomized trial in metastatic non-small-cell lung cancer

artículo científico publicado en 2003

Translational oncogenomics: toward rational therapeutic decision-making

artículo científico publicado en 2002

Treatment of advanced non-small-cell lung cancer in the elderly: results of an international expert panel

artículo científico publicado en 2005

Treatment of brain metastases in non-small cell lung cancer (NSCLC) patients with epidermal growth factor receptor (EGFR) mutations: the role of EGFR tyrosine kinase inhibitors

artículo científico publicado en 2013

Treatment of non-small-cell lung cancer and pharmacogenomics: where we are and where we are going

artículo científico publicado en 2006

Trends in immunotherapy for brain metastases

artículo científico publicado en 2016

Tumor BRCA1, RRM1 and RRM2 mRNA expression levels and clinical response to first-line gemcitabine plus docetaxel in non-small-cell lung cancer patients

artículo científico publicado en 2008

Tumour and serum MGMT promoter methylation and protein expression in glioblastoma patients

artículo científico publicado en 2011

Tyrosine kinase inhibitors for non-small-cell lung cancer: finding patients who will be responsive

artículo científico publicado en 2011

Understanding the function and dysfunction of the immune system in lung cancer: the role of immune checkpoints

artículo científico publicado en 2015

Unraveling the genomic complexity of small cell lung cancer

artículo científico publicado en 2016

Usefulness of circulating free DNA for monitoring epidermal growth factor receptor mutations in advanced non-small cell lung cancer patients: a case report

artículo científico publicado en 2016

Weekly regimen of irinotecan/docetaxel in previously treated non-small cell lung cancer patients and correlation with uridine diphosphate glucuronosyltransferase 1A1 (UGT1A1) polymorphism ⬇️

artículo científico publicado el 1 de noviembre de 2003

Weighing tumor biology in treatment decisions for patients with non-small cell lung cancer

artículo científico publicado en 2007

What new therapeutic targets exist for EGFR-mutant NSCLC?

artículo científico publicado en 2014

Wnt inhibitory factor-1 is silenced by promoter hypermethylation in human lung cancer

artículo científico publicado en 2004

Wnt signaling in stem cells and non-small-cell lung cancer

artículo científico publicado en 2005

XPG mRNA expression levels modulate prognosis in resected non-small-cell lung cancer in conjunction with BRCA1 and ERCC1 expression.

artículo científico publicado en 2009

YB-1 regulates tumor growth by promoting MACC1/c-Met pathway in human lung adenocarcinoma

artículo científico publicado en 2017

c-Met Mutational Analysis in the Sema and Juxtamembrane Domains in Small-Cell-Lung-Cancer

artículo científico publicado en 2006

cfDNA analysis from blood in melanoma

artículo científico publicado en 2015

mRNA expression levels and genetic status of genes involved in the EGFR and NF-κB pathways in metastatic non-small-cell lung cancer patients

artículo científico publicado en 2011

mRNA expression of BRCA1, PIAS1, and PIAS4 and survival after second-line docetaxel in advanced gastric cancer

artículo científico publicado en 2011

Dominio Público Uruguay está sostenido por:

Acerca de Dominio Público Uruguay

Ayuda